Applied Genetic Technologies Corp (NASDAQ:AGTC) reported Q4 2017 earnings this Morning, coming in at ($0.18) per share, missing Wall Street’s estimates of $0.14 per Share. Revenue for the quarter came in at $8.30 million beating analyst estimates of $12.39 million
Analyst Coverage For Applied Genetic Technologies Corp (NASDAQ:AGTC)
These are 3 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Applied Genetic Technologies Corp (NASDAQ:AGTC) is Buy (Score: 2.67) with a consensus target price of $14.63 , a potential (195.45% upside)Recent Insider Trading for Applied Genetic Technologies Corp (NASDAQ:AGTC)
- On 11/16/2016 Ivana Magovcevic, Director, bought 3,000 with an average share price of $9.63 per share and the total transaction amounting to $28,890.00.
- On 11/1/2016 Jeffrey D Chulay, VP, sold 1,000 with an average share price of $7.05 per share and the total transaction amounting to $7,050.00.
- On 9/22/2016 Mark S Shearman, Insider, bought 3,000 with an average share price of $8.87 per share and the total transaction amounting to $26,610.00.
- On 9/20/2016 Stephen W Potter, Insider, bought 1,400 with an average share price of $8.89 per share and the total transaction amounting to $12,446.00.
- On 9/19/2016 Lawrence E Bullock, CFO, bought 10,000 with an average share price of $8.75 per share and the total transaction amounting to $87,500.00.
- On 2/23/2015 Plc Glaxosmithkline, Major Shareholder, sold 503,150 with an average share price of $22.00 per share and the total transaction amounting to $11,069,300.00.
Recent Trading for Applied Genetic Technologies Corp (NASDAQ:AGTC) Shares of Applied Genetic Technologies Corp closed the previous trading session at with shares trading hands.